Non-coding 886 (nc886/ vtRNA2-1), the epigenetic odd duck - implications for future studies

Epigenetics. 2024 Dec;19(1):2332819. doi: 10.1080/15592294.2024.2332819. Epub 2024 Mar 25.

Abstract

Non-coding 886 (nc886, vtRNA2-1) is the only human polymorphically imprinted gene, in which the methylation status is not determined by genetics. Existing literature regarding the establishment, stability and consequences of the methylation pattern, as well as the nature and function of the nc886 RNAs transcribed from the locus, are contradictory. For example, the methylation status of the locus has been reported to be stable through life and across somatic tissues, but also susceptible to environmental effects. The nature of the produced nc886 RNA(s) has been redefined multiple times, and in carcinogenesis, these RNAs have been reported to have conflicting roles. In addition, due to the bimodal methylation pattern of the nc886 locus, traditional genome-wide methylation analyses can lead to false-positive results, especially in smaller datasets. Herein, we aim to summarize the existing literature regarding nc886, discuss how the characteristics of nc886 give rise to contradictory results, as well as to reinterpret, reanalyse and, where possible, replicate the results presented in the current literature. We also introduce novel findings on how the distribution of the nc886 methylation pattern is associated with the geographical origins of the population and describe the methylation changes in a large variety of human tumours. Through the example of this one peculiar genetic locus and RNA, we aim to highlight issues in the analysis of DNA methylation and non-coding RNAs in general and offer our suggestions for what should be taken into consideration in future analyses.

Keywords: DNA methylation; epigenetics; nc886; non-coding RNA; vtRNA2–1.

Publication types

  • Review

MeSH terms

  • DNA Methylation*
  • Epigenesis, Genetic
  • Humans
  • Neoplasms*
  • RNA

Substances

  • RNA

Grants and funding

This research was supported by the Academy of Finland [grants no. 330809, 338395, 322098, 356405], Laboratoriolääketieteen edistämissäätiö sr., the Pirkanmaa Regional Fund of the Finnish Cultural Foundation, Signe och Ane Gyllenbergs stiftelse, state funding for university-level health research, Tampere University Hospital, the Wellbeing Services County of Pirkanmaa [9AC077, 9X047, 9S054, 9AB059 and T63074], the Yrjö Jahnsson Foundation [grants 20207299 and 20197212], and the Finnish Foundation for Cardiovascular Research.